MA35437B1 - Proteines de fusion pour le traitement de troubles du metabolisme - Google Patents

Proteines de fusion pour le traitement de troubles du metabolisme

Info

Publication number
MA35437B1
MA35437B1 MA36824A MA36824A MA35437B1 MA 35437 B1 MA35437 B1 MA 35437B1 MA 36824 A MA36824 A MA 36824A MA 36824 A MA36824 A MA 36824A MA 35437 B1 MA35437 B1 MA 35437B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
metabolic disorders
treatment
fgf21
proteins
Prior art date
Application number
MA36824A
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35437B1 publication Critical patent/MA35437B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'identification de protéines de fusion comprenant des variants de polypeptides et de protéines du facteur de croissance des fibroblastes 21 (fgf21) présentant des propriétés pharmaceutiques améliorées. L'invention concerne également des procédés de traitement de troubles associés au fgf21, y compris des troubles du métabolisme
MA36824A 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme MA35437B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (fr) 2011-09-26 2012-09-26 Protéines de fusion pour le traitement de troubles du métabolisme

Publications (1)

Publication Number Publication Date
MA35437B1 true MA35437B1 (fr) 2014-09-01

Family

ID=46970456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36824A MA35437B1 (fr) 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme

Country Status (41)

Country Link
US (6) US9006400B2 (fr)
EP (2) EP3321276B1 (fr)
JP (4) JP6186361B2 (fr)
KR (1) KR102085605B1 (fr)
CN (2) CN103945871B (fr)
AP (1) AP2014007543A0 (fr)
AR (2) AR088044A1 (fr)
AU (1) AU2012316052A1 (fr)
BR (1) BR112014007069B1 (fr)
CA (1) CA2849464C (fr)
CL (2) CL2014000736A1 (fr)
CO (1) CO6920257A2 (fr)
CR (1) CR20140140A (fr)
CU (2) CU24314B1 (fr)
CY (2) CY1120928T1 (fr)
DK (2) DK2760475T3 (fr)
EA (1) EA039633B1 (fr)
ES (2) ES2689762T3 (fr)
GT (1) GT201400055A (fr)
HR (2) HRP20181558T1 (fr)
HU (2) HUE039857T2 (fr)
IL (1) IL231533B (fr)
IN (1) IN2014DN02043A (fr)
JO (1) JO3476B1 (fr)
LT (2) LT2760475T (fr)
MA (1) MA35437B1 (fr)
MX (1) MX350273B (fr)
MY (1) MY166059A (fr)
PE (2) PE20181159A1 (fr)
PL (2) PL3321276T3 (fr)
PT (2) PT2760475T (fr)
RS (2) RS57868B1 (fr)
SG (2) SG10201602339XA (fr)
SI (2) SI2760475T1 (fr)
SM (1) SMT202100595T1 (fr)
TN (1) TN2014000109A1 (fr)
TW (1) TWI593708B (fr)
UA (1) UA113856C2 (fr)
UY (2) UY34346A (fr)
WO (1) WO2013049247A1 (fr)
ZA (1) ZA201401700B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043692B1 (fr) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Dérivés polysaccharides de l'érythropoïétine
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013006486A2 (fr) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
EP3125921B1 (fr) * 2014-03-11 2020-07-08 Novartis AG Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
WO2016065106A1 (fr) * 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017021893A1 (fr) 2015-08-03 2017-02-09 Novartis Ag Méthode de traitement des troubles associés au fgf21
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
CN109789186A (zh) * 2016-05-25 2019-05-21 得克萨斯系统大学评议会 用于治疗分泌性疾病的方法和组合物
WO2018032638A1 (fr) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 Peptide de liaison pour la construction d'une protéine de fusion
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
BR112019012693A2 (pt) 2016-12-22 2019-11-19 Sanofi combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
DK3619324T3 (da) * 2017-05-05 2025-09-22 Trefoil Therapeutics Inc Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111601613A (zh) * 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (fr) * 2019-05-07 2020-11-11 Atlas Antibodies AB Formulation contenant polypeptides de fusion marques par un isotope
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
TW202135811A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 使用整聯蛋白抑制劑組合治療肝臟疾病
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023540663A (ja) * 2020-07-02 2023-09-26 サノフイ Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質
WO2022101853A1 (fr) 2020-11-16 2022-05-19 Novartis Ag Procédé de détermination de la fibrose hépatique
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (fr) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Utilisations de protéines de fusion fgf21
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
WO2025108432A1 (fr) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Arn circulaire codant pour fgf21 et son utilisation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
EP2295079A3 (fr) 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Methode destinée à traiter l'inflammation
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1673395A1 (fr) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
AU2004303783A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
PL1751184T3 (pl) * 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
DK1789442T3 (da) * 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
WO2006078463A2 (fr) 2005-01-21 2006-07-27 Eli Lilly And Company Methode de traitement de maladie cardio-vasculaire
MX2010013333A (es) * 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
US8785151B2 (en) 2008-10-24 2014-07-22 Bernhard Geierstanger Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
TWI560197B (en) * 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
WO2010148142A1 (fr) * 2009-06-17 2010-12-23 Amgen Inc. Polypeptides fgf19 chimériques et leurs utilisations
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
EP3125921B1 (fr) 2014-03-11 2020-07-08 Novartis AG Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos

Also Published As

Publication number Publication date
HRP20181558T1 (hr) 2018-11-30
CU20140034A7 (es) 2014-08-28
US11944664B2 (en) 2024-04-02
BR112014007069A2 (pt) 2017-03-28
US11129874B2 (en) 2021-09-28
JP2022058546A (ja) 2022-04-12
CY1124697T1 (el) 2022-07-22
CU20150171A7 (es) 2016-07-29
JP6186361B2 (ja) 2017-08-23
SMT202100595T1 (it) 2022-01-10
MX350273B (es) 2017-08-31
EA201490695A1 (ru) 2015-10-30
US20240261372A1 (en) 2024-08-08
CN103945871A (zh) 2014-07-23
JP7339372B2 (ja) 2023-09-05
US9266935B2 (en) 2016-02-23
LT2760475T (lt) 2018-10-25
UY39119A (es) 2021-04-30
US20150166622A1 (en) 2015-06-18
AU2012316052A1 (en) 2014-04-17
CN107266579A (zh) 2017-10-20
HUE039857T2 (hu) 2019-02-28
SG10201602339XA (en) 2016-05-30
CN103945871B (zh) 2017-04-26
SI3321276T1 (sl) 2021-11-30
TW201326213A (zh) 2013-07-01
ZA201401700B (en) 2015-01-28
TN2014000109A1 (en) 2015-07-01
PE20141551A1 (es) 2014-10-26
NZ622998A (en) 2016-07-29
JO3476B1 (ar) 2020-07-05
PL3321276T3 (pl) 2022-01-17
EP3321276B1 (fr) 2021-07-28
EP3321276A2 (fr) 2018-05-16
ES2689762T3 (es) 2018-11-15
JP6567613B2 (ja) 2019-08-28
CA2849464A1 (fr) 2013-04-04
PT2760475T (pt) 2018-10-25
US20160193297A1 (en) 2016-07-07
HRP20211575T1 (hr) 2022-02-04
AR088044A1 (es) 2014-05-07
UY34346A (es) 2013-04-30
RS57868B1 (sr) 2018-12-31
US20180369332A1 (en) 2018-12-27
HK1251238A1 (en) 2019-01-25
IN2014DN02043A (fr) 2015-05-15
DK3321276T3 (da) 2021-10-25
US20130079500A1 (en) 2013-03-28
DK2760475T3 (en) 2018-10-15
CL2014000736A1 (es) 2014-10-03
IL231533B (en) 2018-06-28
BR112014007069B1 (pt) 2020-12-15
KR102085605B1 (ko) 2020-03-06
UA113856C2 (xx) 2017-03-27
PT3321276T (pt) 2021-10-27
EP2760475A1 (fr) 2014-08-06
EP3321276A3 (fr) 2018-06-20
MY166059A (en) 2018-05-22
AP2014007543A0 (en) 2014-03-31
LT3321276T (lt) 2021-11-10
EA039633B1 (ru) 2022-02-18
CL2016002215A1 (es) 2016-10-28
SI2760475T1 (sl) 2018-10-30
CR20140140A (es) 2014-07-15
US12527841B2 (en) 2026-01-20
JP2020007314A (ja) 2020-01-16
US9006400B2 (en) 2015-04-14
PE20181159A1 (es) 2018-07-19
CO6920257A2 (es) 2014-04-10
AR123908A2 (es) 2023-01-25
CU24206B1 (es) 2016-10-28
HUE055584T2 (hu) 2021-12-28
PL2760475T3 (pl) 2018-11-30
SG11201400538QA (en) 2014-06-27
ES2895080T3 (es) 2022-02-17
CN107266579B (zh) 2022-07-12
US10076554B2 (en) 2018-09-18
TWI593708B (zh) 2017-08-01
MX2014003677A (es) 2014-04-30
CA2849464C (fr) 2024-01-30
JP2014534172A (ja) 2014-12-18
RS62341B1 (sr) 2021-10-29
EP2760475B1 (fr) 2018-07-04
KR20140069250A (ko) 2014-06-09
WO2013049247A1 (fr) 2013-04-04
CU24314B1 (es) 2018-02-08
US20210386824A1 (en) 2021-12-16
GT201400055A (es) 2017-09-28
CY1120928T1 (el) 2019-12-11
IL231533A0 (en) 2014-04-30
JP2018023370A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MA34710B1 (fr) Procede de traitement des troubles associes au fgf21
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
PH12018502451A1 (en) Brain delivery protein
MY183712A (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EP3192526A3 (fr) Exosomes d'administration d'agents biothérapeutiques
MX346002B (es) Anticuerpos anti-vegf y sus usos.
EA201492053A1 (ru) Белки фактора роста фибробластов 21
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders
MA37640B1 (fr) Protéines du facteur de croissance des fibroblastes 21
TH145764A (th) วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21
MA37780B1 (fr) Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation
TN2010000348A1 (en) Methods and compositions using klotho-fgf fusion polypeptides